HIV-Associated Malignant Lymphoma

Brunnberg, Uta; Hentrich, Marcus; Hoffmann, Christian; Wolf, Timo; Hübel, Kai

doi:10.1159/000456036

Cited by 34 publications

(21 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several cART regimens with a good safety and tolerability profile and low interaction potential are now available, strongly arguing for a simultaneous cART during ARL chemotherapy. 4 …”

Section: Discussionmentioning

confidence: 99%

“… 1 Patients with ARL are usually treated with the same chemotherapy protocols established in the HIV-negative setting, 2 and the rates of complete remission (CR) achieved are comparable to those reported in their HIV-negative counterparts. 3 , 4 However, available data on the incidence and potential risk factors of recurrent disease in ARL are scarce, and treatment of disease relapse remains challenging. 4 , 5 In recent studies on HIV-negative patients with diffuse large B-cell lymphoma (DLBCL), R- CHOP-based regimens (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone) resulted in CR rates of around 65–80%.…”

Section: Introductionmentioning

confidence: 99%

“… 3 , 4 However, available data on the incidence and potential risk factors of recurrent disease in ARL are scarce, and treatment of disease relapse remains challenging. 4 , 5 In recent studies on HIV-negative patients with diffuse large B-cell lymphoma (DLBCL), R- CHOP-based regimens (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone) resulted in CR rates of around 65–80%. Differences in response rates largely depend on the pre-treatment International Prognostic Index (IPI) for aggressive lymphomas.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study

et al. 2018

Self Cite

View full text Add to dashboard Cite

Outcome of HIV-infected patients with AIDS-related lymphomas has improved during recent years. However, data on incidence, risk factors, and outcome of relapses in AIDS-related lymphomas after achieving complete remission are still limited. This prospective observational multicenter study includes HIV-infected patients with biopsy- or cytology-proven malignant lymphomas since 2005. Data on HIV infection and lymphoma characteristics, treatment and outcome were recorded. For this analysis, AIDS-related lymphomas patients in complete remission were analyzed in terms of their relapse- free survival and potential risk factors for relapses. In total, 254 of 399 (63.7%) patients with AIDS-related lymphomas reached a complete remission with their first-line chemotherapy. After a median follow up of 4.6 years, 5-year overall survival of the 254 patients was 87.8% (Standard Error 3.1%). Twenty-nine patients relapsed (11.4%). Several factors were independently associated with a higher relapse rate, including an unclassifiable histology, a stage III or IV according to the Ann Arbor Staging System, no concomitant combined antiretroviral therapy during chemotherapy and R-CHOP-based compared to more intensive chemotherapy regimens in Burkitt lymphomas. In conclusion, complete remission and relapse rates observed in our study are similar to those reported in HIV-negative non-Hodgkin lymphomas. These data provide further evidence for the use of concomitant combined antiretroviral therapy during chemotherapy and a benefit from more intensive chemotherapy regimens in Burkitt lymphomas. Modifications to the chemotherapy regimen appear to have only a limited impact on relapse rate.

show abstract

“…Several cART regimens with a good safety and tolerability profile and low interaction potential are now available, strongly arguing for a simultaneous cART during ARL chemotherapy. 4 …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Contudo, pacientes com contagem CD4+ < 50 células/ μl devem realizar profilaxia antimicrobiana, administração de fator estimulador de colónias de granulócitos e tratamento das infecções oportunistas, além do uso de TARV. 20 Revista SPDV 76 (1) …”

Section: Discussionunclassified

Penfigóide Bolhoso Refractário em Paciente Infectado pelo Vírus da Imunodeficiência Humana

Thien

Fernandes

Novello

et al. 2018

SPDV

View full text Add to dashboard Cite

7Professor auxiliar e Chefe do Serviço de Dermatologia do Hosp. Univ. Pedro Ernesto (HUPE), Brasil RESUMO -Penfigóide bolhoso, a dermatose bolhosa subepidérmica auto-imune mais comum, é devida a auto-anticorpos contra partículas dos hemidesmosmas (BP180 e/ou BP230) e caracteriza-se por prurido e bolhas cutâneas tensas sobre base eritematosa ou pele normal. Afeta predominantemente idosos, por vezes com comorbilidades neurológicas ou neopláscias. A associação a infecção pelo vírus da imunodeficiência humana é rara. Relatamos o caso de uma paciente jovem VIH+ em tratamento antirretroviral com carga viral indetectável e contagem normal de células T CD4+, que desenvolveu penfigóide bolhoso com lesões extensas, incluindo na mucosa oral, resistentes a vários pulsos de corticoides, corticoides orais e metotrexato, com melhora e estabilidade clínica apenas após uma infusão de rituximab, um anticorpo monoclonal anti-CD20. PALAVRAS-CHAVE -Infecções por HIV; Penfigóide Bolhoso; Rituximab. Refractory Bullous Pemphigoid in HIV-Infected Patient ABSTRACT -Bullous pemphigoid, the most common autoimmune subepidermal blistering disease, is due to autoantibodies against BP180/230 present in the hemodesmosomes of the basal keratinocytes that typically causes pruritus and tense cutaneous bullae on an erythematous or normal skin It affects predominantly the elderly, often in association with neurologic or neoplastic disease. The association with the human immunodeficiency virus infection is rare. We present a case of a young VIH+ patient under antiretroviral therapy with undetectable viral load and normal CD4+ T-cell count who developed an extensive bullous pemphigoid refractory to pulses of corticosteroids, oral steroids and methotrexate and improved only after the infusion of rituximab, an anti-CD20 monoclonal antibody. KEYWORDS -HIV Infections INTRODUÇÃOO penfigóide bolhoso (PB) é uma doença autoimune caracterizada por bolhas subepidérmicas, tensas, pruriginosas, que se localizam sobre a pele sã, eritematosa ou eritematoedematosa, que em cerca de 70% dos casos poupa as mucosas.1 Afeta predominantemente idosos, após os 60 anos, e associa-se frequentemente com doenças neurológicas 1 e outras doenças autoimunes.A associação com a infecção pelo vírus da imunodeficiên-cia humana (VIH) está pouco referenciada na literatura. Os autores relatam um caso de PB em paciente jovem com infecção VIH+ bem controlada com terapia antirretroviral (TARV) que se revelou refratário às terapias convencionais e respondeu bem ao rituximab. RELATO DE CASOUma mulher de 33 anos diagnosticada com infecção por VIH há seis anos, iniciou quadro com lesões urticariformes pruriginosas e pústulas no tronco, com evolução de quatro meses (Fig.1a). Durante internamento em serviço de Dermatologia

show abstract

“…Brunnberg et al [5] focus on HIV-associated lymphomas. Despite the use of intensive protocols in the cART era, the outcome of non-Hodgkin's lymphoma is still worse compared to HIV-negative patients, and the optimal treatment strategy has not been defined yet.…”

mentioning

confidence: 99%